Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 13/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3034959 | 0.82 | NPY5R (0.54) | NPY5RADRA1AKCNH2 | |
| SCHEMBL3034957 | 0.82 | NPY5R (0.54) | NPY5RADRA1AKCNH2 | |
| SCHEMBL3035637 | 0.81 | NPY5R (0.55) | NPY5RADRA1AKCNH2GRM5 | |
| SCHEMBL3741234 | 0.81 | NPY5R (0.55) | NPY5RADRA1AKCNH2GRM5 | |
| SCHEMBL3668430 | 0.80 | NPY5R (0.54) | NPY5RADRA1AKCNH2GRM5 | |
| SCHEMBL3668431 | 0.80 | NPY5R (0.54) | NPY5RADRA1AKCNH2GRM5 | |
| SCHEMBL738190 | 0.79 | NPY5R (0.52) | NPY5RADRA1AKCNH2GRM5 | |
| SCHEMBL3028742 | 0.79 | NPY5R (0.53) | NPY5RADRA1AKCNH2GRM5 | |
| Lithium Ion SCHEMBL3021432 | 0.78 | NPY5R (0.52) | NPY5RADRA1AKCNH2GRM5 | |
| SCHEMBL736419 | 0.77 | GRM5 (0.52) | NPY5RGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20090137576-A1 | Novel Piperidine Derivative | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137576-A1 | Novel Piperidine Derivative | HRH4, HRH3, HRH1 | NPY5R 385/4885ADRA1A 103/4885KCNH2 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.